Author:
Zeng Jianfeng,Huang Huan,Liu Xuhui,Huang Zhen,Liu Weijian,Liu Houming,Lu Shuihua
Abstract
AbstractThe Xpert MTB/RIF test (Xpert) can help in the accurate screening of tuberculosis, however, its widespread use is limited by its high cost and lack of accessibility. Pooling of sputum samples for testing is a strategy to cut expenses and enhance population coverage but may result in a decrease in detection sensitivity due to the dilution of Mycobacterium tuberculosis (Mtb) by sample mixing. We investigated how the mixing ratio affected the detection performance of Xpert. We used frozen sputum samples that had been kept after individual Xpert assays of the sputa from Mtb-confirmed TB patients and non-TB patients. Our results showed that the overall sensitivity of the Xpert pooling assay remained higher than 80% when the mixing ratio was between 1/2 and 1/8. When the mixing ratio was raised to 1/16, the positive detection rate fell to 69.0%. For patients with either a high sputum Mtb smear score ≥ 2+, a time-to-positive culture ≤ 10 days, or an Xpert test indicating a high or medium abundance of bacteria, the pooling assay positivity rates were 93.3%, 96.8%, and 100% respectively, even at a 1/16 mixing ratio. For participants with cavities and cough, the pooling assay positivity rates were 86.2% and 90.0% at a 1/8 ratio, higher than for those without these signs. Our results show that the Xpert pooled assay has a high overall sensitivity, especially for highly infectious patients. This pooling strategy with lower reagent and labor costs could support TB screening in communities with limited resources, thereby facilitating reductions in the community transmission and incidence of TB worldwide.
Funder
the Special Fund for Science and Technology Innovation of Guangdong
the Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties
Shenzhen Natural Science Foundation
the Shenzhen Clinical Research Center for Tuberculosis
the Special Fund Of Shenzhen Central-leading-local Scientific and Technological Foundation
Publisher
Springer Science and Business Media LLC
Reference9 articles.
1. WHO. Global tuberculosis report 2022. Geneva: World Health Organization. In.; 2022.
2. WHO. Global tuberculosis report 2021. Geneva: World Health Organization. In.; 2021.
3. WHO Guidelines Approved by the Guidelines Review Committee. In: WHO consolidated guidelines on tuberculosis: Module 2: screening– systematic screening for tuberculosis disease. edn. Geneva: World Health Organization© World Health Organization 2021.; 2021.
4. Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, Cuevas LE, McHugh TD, Zijenah L, Kapata N, et al. Advances in Tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis. 2013;13(4):349–61.
5. Abdurrahman ST, Mbanaso O, Lawson L, Oladimeji O, Blakiston M, Obasanya J, Dacombe R, Adams ER, Emenyonu N, Sahu S, et al. Testing pooled sputum with Xpert MTB/RIF for diagnosis of Pulmonary Tuberculosis to increase affordability in low-income countries. J Clin Microbiol. 2015;53(8):2502–8.